Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new long-term data highlighting the sustained survival benefits of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 ...
Use of Hydroxyurea in Severe Forms of Sickle Cell Disease: Study of 60 Pediatric Cases in Senegal ()
Severe forms of SCD: SCD with/or (kidney damage; priapism; stroke; acute chest syndrom; acute osteonecrosis of femoral head; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback